BioPartnering Europe Offers a Host of Partnering and Networking Opportunities

As BioPartnering Europe (BPE) enters its 14th year, it
continues to stand out as the top European life sciences conference
for partnering and business networking opportunities. With nearly 1000
delegates now registered and more than 500 meetings organized so far
through www.biopartnering.com, this year's BPE looks to be one of the
most successful yet. BioPartnering Europe will again be held in
London, UK, on October 8-10th 2006.

biopartnering.com & video profiles foster B2B opportunities

BPE delegates will once again be able to search partnering
opportunities through keyword searches of detailed profiles on all
companies, contact other delegates, arrange private meetings, and
reserve meeting rooms in advance of the conference. In addition,
biopartnering.com now offers a unique component -- video profiles.
This exciting new feature will give Open House and Emerging Company
presenters the ability to add a short video to their biopartnering.com
profile and thus promote their company in a dynamic and engaging
manner.

Networking opportunities

As well as is its innovative and informative program which
features some of the hottest topics in the biotech industry today, BPE
also offers a host of partnering and networking opportunities enabling
delegates to meet potential partners and investors in both formal and
informal settings. BPE will be opened on the evening of Sunday,
October 8th by a reception sponsored by International Business Wales,
which will acknowledge the growing importance of Wales as a biotech
centre in Europe. "BioPartnering Europe remains one of the best
networking conferences to attend," stated Barbara Sawitsky, Director
of Corporate Development for OSI Pharmaceuticals, Inc. "The partnering
scheduling software really provides added benefit for all attendees."

Dinner Reception at Spitalfields

A highlight of BPE for delegates is the annual dinner reception
which will be held on October 9th at Christ Church Spitalfield's, one
of London's architectural treasures. The magnificent interior which is
300 years old, is one of the finest examples of Baroque architecture
in the UK and will provide the perfect venue for an evening of
informal networking.

Life Sciences Partnering China and Europe Forum

BioPartnering Europe has been selected by the European Commission
as the partner for the 2nd European Forum of the Life Sciences
Partnering China and Europe Forum, which is to be held on October 11,
2006, the day after BPE commences. The Forum aims to promote
partnerships, joint ventures, and collaborations between emerging
European biotech companies and their development agencies and the
Chinese life science industry as well as to learn more about the
strategic opportunities and challenges of working in and with China,
and all BPE registered attendees may attend this event free of charge.
-0-
*T
Conference Sponsors and Supporters

Producer:
Technology Vision Group LLC

Platinum Sponsors
AstraZeneca and Taylor Wessing

Gold Sponsors
Cooley Godward LLP, Deloitte, Ferghana Partners Group, and Wyeth

Silver Sponsors
Amgen, Bristol-Myers Squibb Company, Genentech, GlaxoSmithKline
plc, International Business Wales, Johnson & Johnson, Merck & Co.,
Inc., Novartis, Pfizer, Procter & Gamble, Roche, and TAP
Pharmaceutical Products Inc.

Conference Sponsors
BioQuebec, Farris, Vaughan, Wills, & Murphy LLP, Genzyme, Life
Science Analytics, Inc., NovaQuest, and Solomon-Page Group LLC

Conference Supporters
BayBio, BioCentury, Business Wire, Citigate, European
Biopharmaceutical Review, Global Bioscience Partnership, Nature
Biotechnology, Red Herring, and the U.S. Commercial Service

Official Carrier
British Airways

Emerging Company Presenters
Adnexus Therapeutics, Alchemia Limited, Amorfix Life Sciences
Ltd., Antibe Therapeutics Inc., Athenagen, Inc., Avexa, BioXell SpA,
Borean Pharma A/S, BT Pharma, Celldex Therapeutics, Clera Inc.,
CrystalGenomics, Inc., EcoBiotics Ltd, GammaCan Int. Inc, Haptogen
Ltd, hemoCORM Ltd, Karus Therapeutics, Lymphosign Inc., Merrion
Pharmaceuticals Limited, Mimetogen Pharmaceuticals, MNLpharma Ltd.,
ODC Therapy, PolyMedix Inc., ProtAffin Biotechnologie AG, Psynova Ltd,
Rincon Pharmaceuticals, Inc., SantoSolve, Senexis Limited, Syntaxin,
Y's Thera, and Zyentia Limited

Open House Presenters
ACE BioSciences A/S, Aegera Therapeutics Inc., AerovectRx
Corporation, Affibody AB, Algeta ASA, AlgoNomics NV, Alligator
Bioscience, amaxa GmbH, Ambit Biosciences, AmpliMed Corporation,
Antisoma, Array BioPharma Inc., Arrow Therapeutics Ltd., Aspreva
Pharmaceuticals, Astex Therapeutics Ltd., Cambridge, Cambridgeshire,
United Kingdom, Avecia Biotechnology, Avera Pharmaceuticals, Inc.,
Avid Bioservices, Inc., Avidex, Banner Pharmacaps, BioFocus DPI /
Galapagos, Biolex Therapeutics, Biota Holdings Limited, Boston Life
Sciences, Inc., Callisto Pharmaceuticals, Cell Genesys, Inc.,
Chemokine Therapeutics Corp., CombinatoRx, CovX, Curis, Inc., Cygenics
Ltd, Cylene Pharmaceuticals Inc., Cytokinetics, Inc., Dako North
America, Digilab BioVisioN GmbH, Dimera Incorporated, Direvo Biotech
AG, Dyax Corp., Emergent Product Development UK Ltd, Evolutec Group
Plc, Evotec, ExonHit Therapeutics, Faust Pharmaceuticals, Favrille,
Inc., Gala Biotech, a business unit of Cardinal Health, GangaGen Inc.,
Health Protection Agency, Icagen, Inc., ImmuPharma PLC, INC Research,
Indevus Pharmaceuticals, Inc., Ingenium Pharmaceuticals AG, InNexus
Biotechnology Inc., Intendis GmbH, Intermune, Inc., Istituto Superiore
di Sanita, Jurilab Ltd., Liponex Inc., Locus Pharmaceuticals, Inc.,
MaxCyte, Inc., Medicago Inc., MedPharm Ltd, Miltenyi Bioprocess,
MolMed SpA, MorphoSys AG, Nektar Therapeutics, Nerites Corporation,
Neuren Pharmaceuticals Ltd, Novation Pharmaceuticals Inc., Novozymes
A/S, OctoPlus, Orient Europharma Co., Ltd., Oxford Genome Sciences,
Oxxon Therapeutics Ltd, Paradigm Therapeutics Ltd, Perceptronix
Medical Inc., Phylogica Ltd, PLx Pharma Inc., PTC Therapeutics, Inc.,
RNTECH/DNAVision, Scottish Biomedical, SGX Pharmaceuticals, Inc.,
Simcere Pharmaceutical Incorporation, SR Pharma plc. / Atugen AG, Stem
Cell Therapeutics, Symphogen A/S, Synta Phamaceuticals Corp.,
Threshold Pharmaceuticals, TiGenix NV, TopoTarget UK Ltd, Transgene
S.A., Tranzyme Pharma, Trigen Holdings AG, Tripos Discovery Research
Ltd., UCB Celltech, Warwick Effect Polymers Ltd., Welichem Biotech
Inc., Xenome Ltd, XOMA Ltd., and ZIOPHARM Oncology, Inc.

*T